CONTRACT VARIATION AGREEMENT No.2Contract Variation Agreement • October 25th, 2021
Contract Type FiledOctober 25th, 2021Contract/Variation Reference: NHS England and BioMarin entered into a Managed Access Agreement (“MAA”) incorporating the commercial element of managed access agreement (“CAA”) dated 25th November 2015 as varied by Contract Variation Agreement No.1 dated 15th December 2020, relating to the supply of elosulfase alfa (Vimizim) for the treatment of mucopolysaccharidosis type IVs.